Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer

  • STATUS
    Recruiting
  • participants needed
    600
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 23 January 2021
pneumonia
cancer
lung cancer
thoracotomy
endobronchial ultrasonography
lung carcinoma

Summary

This is a national study that involves the participation of 600 lung cancer patients indicated that treatment is ablation of the pulmonary lobe. This technique is called lobectomy.

Lobectomy may be performed in two different ways:

  • Thoracotomy, which is the first reference approach and that is to make a large incision in the chest to pass between the ribs and spread the order to ablate the lobe.
  • By video-thoracoscopy, which is a new surgical approach consisting in practice several small incisions in the chest wall to allow the introduction of a camera and special instruments to ablate the lobe.

The mini-invasive nature of video-thoracoscopy has a positive impact on postoperative expectoration and ventilation. As a result, the incidence of postoperative respiratory complications including atelectasis, pneumonia and Acute Respiratory Distress Syndrome (ARDS) is reduced. These respiratory complications are responsible for prolonged stays in Intensive Care Unit (ICU) and overall hospitalisation. It also has an impact on recovery and quality of life when patients return home. The reduction in the incidence of complications should counterbalance the additional cost of video-thoracoscopy.

This study aims to evaluate the effectiveness of these two techniques in relation to the quality of life and the costs they generate.

Patients who agree to participate in the study were assigned to one or other of these groups (technical thoracotomy or video-thoracoscopy technique) by lot.

Details
Condition Pulmonary Disease, Lung Neoplasm, Bronchial Neoplasm, Lobectomy, Lung Cancer, Lung Disease, carcinoma lung, lung carcinoma
Treatment Video-thoracoscopy, thoracotomy, thoracotomy
Clinical Study IdentifierNCT02502318
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients who have given their consent
Any patient with proven or suspected lung cancer treated by lobectomy
Patients with a negative mediastinoscopy or negative " EBUS-EUS " following a PET scan showing uptake in mediastinal lymph nodes in the preoperative examination
Age between 18 and 80 years
Patient affiliated to a social security regimen
Patients with a WHO performance status equal to 0 or 1

Exclusion Criteria

Adults under wardship
Pregnant or breast-feeding women
Tumours in contact with the pulmonary artery or developing in the lobar bronchi after bronchial fibroscopy
Tumours in contact with the costal periosteum or invading the chest wall
Tumours invading the mediastinal pleura or structures of the mediastinium (superior vena cava, trachea, the main-stem bronchi, aorta, oesophagus, vertebrae)
Tumours invading the diaphragm
Tumours invading the neurovascular structures of the apex (brachial plexus, subclavicular artery, subclavicular vein) causing Pancoast-Tobias syndrome
Patients with histologically-proven contralateral or supraclavicular lymph node (N3) involvement whatever the harvesting method
Patients with a positive mediastinoscopy or positive "EBUS-EUS" following a "PET scan" with uptake in one or more mediastinal lymph nodes
Patients with metastasis (brain, bone, liver, adrenal glands, contralateral lung, pleura)
Patients who have undergone neo-adjuvant chemotherapy and/or radiotherapy
Patients included in a neo-adjuvant chemotherapy and/or radiotherapy protocol
Patients who have already undergone thoracotomy
Patients with decompensated heart failure or with a systolic ejection fraction below 30%
Patients with severe pulmonary artery hypertension
Patients with untreated valve disease
Patients with unstable angina despite appropriate treatment
Patients with untreated carotid stenosis greater than 70%
Patients with histologically proven cirrhosis with various decompensations or who have presented haemoptysis because of oesophageal varicose veins
Patients with severe neurological sequellae (hemiplegia, paraplegia, tetraplegia)
Patients presenting severe psychiatric disorders (dementia, psychosis)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note